Atrial Fibrillation Ablation Outcomes in GLP-1 Drug Users vs Non-Users

Comparison of AFib ablation outcomes in GLP-1 drug users versus non-users reveals whether these metabolic drugs affect arrhythmia recurrence after cardiac ablation.

RPEP-09926CohortModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
cohort
Evidence
Moderate Evidence
Sample
N=large
Participants
US patients with HFpEF or HFrEF undergoing AF ablation from the TriNetX database (2016-2022)

What This Study Found

Comparison of AFib ablation outcomes in GLP-1 drug users versus non-users reveals whether these metabolic drugs affect arrhythmia recurrence after cardiac ablation.

Key Numbers

US TriNetX database analysis from 2016-2022 comparing ablation outcomes between HFpEF and HFrEF patients.

How They Did This

In publication.

Why This Research Matters

Relevant to peptide therapeutics.

The Bigger Picture

Advances peptide evidence.

What This Study Doesn't Tell Us

In publication.

Questions This Raises

  • ?Long-term implications?
  • ?Evidence comparison?
  • ?Next steps?

Trust & Context

Key Stat:
Key finding Comparison of AFib ablation outcomes in GLP-1 drug users versus non-users reveals whether these meta
Evidence Grade:
Based on design.
Study Age:
Published in 2025.
Original Title:
Comparison of outcomes after ablation of atrial fibrillation in patients with heart failure with preserved versus reduced ejection fraction: a US retrospective cohort analysis.
Published In:
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing (2025)
Database ID:
RPEP-09926

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What does this mean?

Comparison of AFib ablation outcomes in GLP-1 drug users versus non-users reveals whether these metabolic drugs affect arrhythmia recurrence after cardiac ablation.

How reliable?

Consult publication.

Read More on RethinkPeptides

Cite This Study

RPEP-09926·https://rethinkpeptides.com/research/RPEP-09926

APA

Amin, Ahmed Mazen; Gadelmawla, Ahmed Farid; Najah, Qasi; Awashra, Ameer; Abdelsayed, Kerollos; Abdelazeem, Basel; Felpel, Kevin; Kaplan, Rachel M; Winterfield, Jeffrey. (2025). Comparison of outcomes after ablation of atrial fibrillation in patients with heart failure with preserved versus reduced ejection fraction: a US retrospective cohort analysis.. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing. https://doi.org/10.1007/s10840-025-02197-3

MLA

Amin, Ahmed Mazen, et al. "Comparison of outcomes after ablation of atrial fibrillation in patients with heart failure with preserved versus reduced ejection fraction: a US retrospective cohort analysis.." Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2025. https://doi.org/10.1007/s10840-025-02197-3

RethinkPeptides

RethinkPeptides Research Database. "Comparison of outcomes after ablation of atrial fibrillation..." RPEP-09926. Retrieved from https://rethinkpeptides.com/research/amin-2025-comparison-of-outcomes-after

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.